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Abstract objective To provide a systematic review of economic evaluations that has been conducted for
onchocerciasis interventions, to summarise current key knowledge and to identify research gaps.
method A systematic review of the literature was conducted on the 8th of August 2018 using the
PubMed (MEDLINE) and ISI Web of Science electronic databases. No date or language stipulations
were applied to the searches.
results We identified 14 primary studies reporting the results of economic evaluations of
onchocerciasis interventions, seven of which were cost-effectiveness analyses. The studies identified
used a variety of different approaches to estimate the costs of the investigated interventions/
programmes. Originally, the studies only quantified the benefits associated with preventing blindness.
Gradually, methods improved and also captured onchocerciasis-associated skin disease. Studies found
that eliminating onchocerciasis would generate billions in economic benefits. The majority of the
cost-effectiveness analyses evaluated annual mass drug administration (MDA). The estimated cost per
disability-adjusted life year (DALY) averted of annual MDA varies between US$3 and US$30 (cost
year variable).
conclusions The cost benefit and cost effectiveness of onchocerciasis interventions have
consistently been found to be very favourable. This finding provides strong evidential support for the
ongoing efforts to eliminate onchocerciasis from endemic areas. Although these results are very
promising, there are several important research gaps that need to be addressed as we move towards
the 2020 milestones and beyond.
keywords onchocerciasis, river blindness, economic evaluations, cost effectiveness, cost-benefit
analyses, cost, elimination, health economics
Introduction
Human onchocerciasis, also known as ‘river blindness’, is
a parasitic infection caused by the filarial nematode
Onchocerca volvulus. It is transmitted by the bites of
Simulium blackflies. Of the 120 million people at risk,
99% live in sub-Saharan Africa, although the disease has
also been endemic in six countries of Latin America and
is present in Yemen [1]. Symptoms can include severe
itching, disfiguring skin conditions, visual impairment,
and permanent blindness [1]. Onchocerciasis is the
world’s second leading infectious cause of blindness after
trachoma [2]. Onchocerciasis can also cause excess mor-
tality [3–5] and is associated with epilepsy, nodding
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syndrome and hyposexual dwarfism (Nakalanga syn-
drome) [6–8].
During the last 40 years, there has been a remarkable
expansion of onchocerciasis control programmes world-
wide [9–14], summarised in Box 1. These programmes
have had a large impact on reducing onchocerciasis as a
public health problem. Initially, control programmes (i.e.
the Onchocerciasis Control Programme in West Africa
(OCP)) only used large-scale vector control as the drugs
available at that time were too toxic for large-scale use.
This changed in 1987, when ivermectin (produced under
the brand name Mectizan), a drug suitable for mass
treatment, was registered for human use against
onchocerciasis, and large-scale chemotherapeutic control
programmes became feasible [11].
In 1987, Merck & Co. committed to supply ivermectin
to onchocerciasis endemic countries ‘as much as neces-
sary for as long as necessary’ [15, 16]. Over 7.8 billion
ivermectin tablets have been donated for the treatment of
onchocerciasis and lymphatic filariasis [17]. This unprece-
dented donation allowed onchocerciasis control in ende-
mic areas where vector control was not feasible or too
expensive to sustain and ivermectin began to be dis-
tributed in the late 1980s. Initially, mobile teams of paid,
local health professionals were used to distribute iver-
mectin; however, this was costly [18], and programmes
mostly switched to using volunteer distributors and com-
munity-directed approaches (Box 1).
Motivated by the successful elimination of the infection
in some foci of Mali and Senegal [19, 20], there was a
shift in onchocerciasis control policy in Africa, with the
aim of programmes changing from elimination as a pub-
lic health problem to elimination of transmission and
ultimately infection. In 2012, the Joint Action Forum of
the African Programme for Onchocerciasis Control
(APOC), chaired by WHO and the ministers of health of
endemic countries, set the target at elimination in 80%
of African countries by 2025 [21]. WHO’s roadmap on
neglected tropical diseases (NTDs) also included goals for
the elimination in several African countries by 2020 [22].
The coverage of NTD mass drug administration
(MDA) programmes has notably expanded over the last
10 years. In 2017, 1.762 billion treatments were deliv-
ered worldwide [23]. NTD control programmes are
becoming increasingly integrated, moving towards target-
ing multiple diseases within a multipronged programme
[24, 25]. In May 2016, the WHO launched the Expanded
Special Project for Elimination of Neglected Tropical Dis-
eases (ESPEN), a five-year project to provide national
NTD programmes with technical and fundraising support
to help them accelerate the control and elimination of
NTDs amenable to preventive chemotherapy, namely
onchocerciasis, lymphatic filariasis, schistosomiasis, soil-
transmitted helminthiases and trachoma [26]. The inte-
grated and cross-sectorial response to NTD control is rel-
evant to the Sustainable Development Goals, including
among others Universal Health Coverage, Water
Box 1 Summary of the control programmes
The Onchocerciasis Control Programme in West
Africa (OCP, 1974–2002): The OCP was launched in
1974–1975, and originally covered a core area in
seven countries of West Africa [11]. However, by
1990 the OCP had expanded its operations to include
larger zones and four additional countries following
the southern and western extensions [10, 11]. From
1974 to 1988 the OCP focused on a strategy of
weekly aerial larviciding of blackfly breeding sites. In
1987 ivermectin was registered for human use against
onchocerciasis, and due to the suitability of this drug
for mass treatment, large-scale chemotherapeutic con-
trol programmes became feasible [10]. Large-scale
mass drug administration (MDA) of ivermectin began
in the OCP regions in the late 1980s, initially admin-
istered by mobile teams of paid, local health profes-
sionals [10].
African Programme for Onchocerciasis Control
(APOC, 1995–2015): The APOC was initiated in
1995 including 19 African countries [11, 149]. The
programme pioneered a community-directed treatment
approach, within which the local communities rather
than health services directed the treatment process;
the treatments were delivered by volunteer commu-
nity-directed distributors (CDDs) [149–151]. APOC
gradually expanded and by 2014 it had a network of
over 699 656 volunteer CDDs [151]. When the pro-
gramme concluded at the end of 2015 it was support-
ing onchocerciasis control and elimination activities in
31 African countries (including the 19 original signa-
tories of the Memorandum, South Sudan, and the 11
ex-OCP participating countries) [149].
The Onchocerciasis Elimination Program for the
Americas (OEPA, 2002–present): The OEPA started
in 1992 in six countries of the Americas (across 13
discrete foci) [11, 12]. The strategy is based on the
biannual (twice a year) distribution of ivermectin, to
all endemic communities (covering at least 85% of
the eligible population) [12]. As of December 2016, a
total of four countries have successfully completed the
World Health Organization process for verification of
elimination [152].
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Sanitation and Hygiene (WASH) initiatives, global part-
nerships, alleviating poverty and hunger and improving
education and economic growth [27].
The aim of this paper was to provide a systematic
review of economic evaluations that have been conducted
for onchocerciasis interventions, to summarise current
key knowledge and to identify research gaps in this area.
Methods
Search strategy
A systematic review of the literature was conducted on the
8th of August 2018 using the PubMed (MEDLINE) and ISI
Web of Science electronic databases. Variants of the fol-
lowing search terms were used to find relevant papers: river
blindness, onchocerciasis, cost(s), cost-benefit, cost-effec-
tiveness, economic(s), economic evaluation. No date or
language stipulations were applied to the searches. A more
detailed summary of the search terms and the PRISMA
checklist are supplied in Appendix S1. The titles and
abstracts of all the identified papers were examined ini-
tially for relevance and then the bibliographies of papers
suitable for inclusion were scanned for studies not origi-
nally retrieved from the databases. The full selection pro-
cess is outlined in Figure 1. Studies relating to cost
recovery and willingness to pay were not explicitly
included as an outcome of the systematic literature search
(but are referenced within the review where relevant).
Results and discussion
We identified 14 primary studies reporting the results of
economic evaluations of onchocerciasis interventions,
which are described in Tables 1 and 2. It is important to
note that both the OCP and APOC expanded over time
(Box 1) and it was not always clear which specific coun-
tries/areas were being included in the different analyses.
Estimated cost of onchocerciasis interventions
A key component of any cost-benefit or cost-effectiveness
analysis (Box 2) of an intervention is its estimated cost.
The studies identified used a variety of different
approaches to estimate the costs of the investigated inter-
ventions/programmes. Many of the studies based their
costs on programme budgets/reports and very few were
based on comprehensive costing studies/approaches.
There was variation in what types of costs were included
within the analyses.
The estimated intervention costs tended to be higher for
the studies evaluating OCP activities. This is likely
because the control measures used by the OCP (vector
control and mass treatment delivered via mobile teams)
were more expensive than the community-directed treat-
ment approach subsequently used by other programmes
[28] (Box 1). The nominal financial cost (i.e. not adjusted
for inflation or discounted) of the OCP (1974–2002) was
just under US$1 billion [29] whereas the projected cost of
the larger APOC (1995–2015) was US$478 million [30].
Often it was difficult to compare the reported costs
from the different studies, as it was not always clear how
costs were estimated, what activities were costed, and
whether reported values were discounted or not. Some
studies appeared only to adjust the costs for inflation and
not discount them (Box 3).
The studies evaluating programmes using community-
based mass treatment generally assumed delivery costs of
around US$0.50 per treatment. This is consistent with the
findings of a systematic review by Keating et al. [31], in
which the average of identified onchocerciasis-specific cost
estimates was US$0.46 per treatment, as well as with
recent MDA cost benchmarks estimated by the WHO [32,
33]. However, it is important to note that the costs of
MDA delivery vary across different settings. An important
driver in this variation is the size of the targeted population
[34–36]. This is because MDA programmes generate
economies of scale; as the number of people treated
increases, the cost per treatment tends to decrease [37, 38].
NTD control programmes have also become increasingly
integrated and instead of using separate disease-specific
programmes they now often target multiple diseases within
one programme. This can result in economies of scope,
reducing the overall cost of the NTD interventions [31,
37–43]. Most of the studies identified did not consider the
potential impact of economies of scale or scope on the
costs of the interventions within their analyses.
There are very few studies that have investigated the
costs of alternative onchocerciasis interventions to annual
community-directed MDA (with ivermectin) [32]. Turner
et al. [44] found that the yearly cost of a community-
directed ivermectin treatment programme increases by
50–60% when increasing the treatment frequency from
once to twice a year.
Several studies also considered the potential for cost-
recovery/cost-sharing, where the communities contribute
financially to the cost of the programme [28, 45–47] and
the participants’ willingness to pay for ivermectin treat-
ment [48, 49].
Economic costs vs. financial costs. The majority of the
studies considered only the financial costs of the interven-
tion. However, when performing economic evaluations of
healthcare interventions, it is typically recommended to
© 2019 The Authors. Tropical Medicine & International Health published by John Wiley & Sons Ltd. 3
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use ‘economic costs’ [50, 51] (Box 2). These conceptu-
alise costs in a broader way than do financial costs and
represent the full value of all resources used for an inter-
vention, including the value (opportunity cost) of
donated resources. Economic costs are important as they
reflect the sustainability and replicability of interven-
tions.
Ndyomugyenyi et al. [34] found that when accounting
for the salaries of governmental personnel and the oppor-
tunity cost incurred by the volunteer community-directed
distributors (CDDs – Box 2), community-directed treat-
ment with ivermectin in Uganda cost US$0.78 per treat-
ment (2004 prices). However, if these costs were
excluded, the cost fell to just US$0.17 per treatment
(2004 prices). The difference between the financial and
economic costs was smaller (US$0.39 vs. US$0.45 (2011
prices)) in a study in Ghana [44].
A key economic cost for many MDA programmes is
the value of the unpaid contribution of the volunteer
CDDs. Turner et al. [52] found that the average eco-
nomic costs relating to the volunteer CDDs unpaid time
can be significant, varying between US$0.05–0.16 per
treatment (cost year variable). They estimated that the
time donated by volunteer CDDs to APOC (1997–2015)
would be valued between US$60–90 million [52].
Economic value of ivermectin. Some of the identified
studies considered the economic value of the donated
ivermectin within their cost-effectiveness analysis. Most
used the quoted commercial value from the Mectizan
Donation Program, i.e. US$1.50 (and US$0.0018 in
shipping costs) per tablet. Assuming that, on average, a
treatment requires 2.8 tablets, this results in an esti-
mated average economic value of donated ivermectin of
US$4.21 per treatment [30]. Kim et al. [53] assumed a
different economic value of US$1.5054 per treatment.
Over the past 30 years, Merck & Co. has donated over
2.7 billion treatments of ivermectin for onchocerciasis
and lymphatic filariasis [16]. Based on these different
assumed valuations of ivermectin this donation would
be valued between US$4–11 billion.
In the context of these economic evaluations, it
should be noted that it is difficult to estimate the true
economic value of a donated drug [54]. This is because
the manufacturing costs of drugs are proprietary infor-
mation, and the donating company may potentially miti-
gate some of the cost through charitable tax write-offs
as well as intangible benefits, such as enhanced public
image among shareholders and employees [55]. It is also
argued that if ivermectin were not donated, it could
potentially be procured from other sources at less than
the proprietary cost. For example, Hernando et al. [55]
estimate the price of an annual 9 mg ivermectin treat-
ment with generic drugs on the global market [56] to
be approximately US$0.78. Based on this, they esti-
mated the direct cost for the tablets donated during
2005–2011 to be US$600 million, compared with the
stated value of US$3.8 billion [55], and with potential
tax write-offs their net cost could be around US$180
million [55].
These arguments need to be interpreted with caution.
Firstly, there is the issue of drug quality, which is a
major challenge in low-income countries, and especially
with anthelmintics and similar popular drugs which
commonly attract counterfeit manufacturers. Secondly,
the donations themselves have a chilling effect on the
markets, driving generic prices downwards. There is in
fact, no established way to estimate the ‘real’ market
price of these drugs, and it is notable that even the low-
est estimates of the value of the donations are very sub-
stantial, measured in hundreds of millions of dollars per
year. What is clear is that the ivermectin donation was
the first substantial donation of its type, and its success
led to the concept of the NTDs as solvable diseases of
poverty, and to the massive donation of some 1.5 bil-
lion treatments for a range of NTDs by some 14 other
pharmaceutical companies during the London Declara-
tion [57].
The foundation of onchocerciasis control programmes
is based on the commitment of ivermectin donation from
Merck & Co. for as long as needed [17, 57]. Therefore,
it is debatable when the value of ivermectin should be
included within an economic evaluation.
Estimated economic benefits and cost-benefit analyses of
onchocerciasis interventions
We identified several cost-benefit analyses of onchocercia-
sis interventions (Table 1). The estimated internal rate of
return (IRR - Box 2) ranged from between 11–20% for the
OCP and 17–24% for APOC (for comparison, an IRR
above 10% is considered by the World Bank as the stan-
dard for a successful public health programme [58])
(Table 1). The estimated net present values (NPV) were
between US$8 million to US$3.7 billion for OCP and US
$54–307 million for APOC (cost years variable). However,
there was variation between the different studies regarding
the time frame considered and the discount rate used
(Box 3), making it difficult to compare the results directly.
None of the cost-benefit analyses identified included the
economic value of the donated ivermectin tablets in their
base case analysis (Table 1). Waters et al. [18] highlighted
that this value could outweigh the estimated economic ben-
efits from both the OCP and APOC programmes.
4 © 2019 The Authors. Tropical Medicine & International Health published by John Wiley & Sons Ltd.
Tropical Medicine and International Health volume 00 no 00
H. C. Turner et al. Economic evaluations of onchocerciasis interventions
More recently, Redekop et al. [59] and Kim et al. [60]
quantified the economic benefits associated with
onchocerciasis elimination. Both those studies found that
eliminating onchocerciasis would generate billions in eco-
nomic benefits (Tables 1 and 3).
The identified studies quantified three different types of
economic benefits of onchocerciasis interventions
(namely, productivity gains, land use gains and reduc-
tions in outpatient services and out-of-pocket expendi-
tures), but there was variation across the studies
regarding how and which economic benefits were quanti-
fied (Table 3). Many of the broader benefits of onchocer-
ciasis in terms of the Millennium Development Goals are
highlighted by Dunn et al. [61].
Productivity gains. Onchocerciasis-associated morbidity
can affect an individual’s economic productivity. Lenk
et al. [62] recently conducted a systematic review of the
productivity losses related to the NTDs eligible for pre-
ventive chemotherapy and a summary of the studies they
identified for onchocerciasis is presented in Table 4.
Unsurprisingly, the degree of the productivity loss was
dependent on the type of onchocerciasis morbidity. Pro-
ductivity losses were highest for blindness and lowest for
skin disease.
A key component of estimating the economic benefits
of onchocerciasis interventions is the productivity gains
that result from preventing onchocerciasis morbidity. The
cost-benefit analyses identified appeared to estimate only
the productivity gains associated with preventing
onchocerciasis-associated blindness. However, the pro-
ductivity losses associated with onchocerciasis-associated
skin disease and visual impairment are also significant
(Tables 4 and 5). Consequently, only quantifying the pro-
ductivity gains associated with prevented cases of blind-
ness underestimates the economic benefits of
onchocerciasis interventions [63].
In contrast, both Kim et al. [60] and Redekop et al.
[59] included the productivity gains associated with pre-
venting onchocerciasis-associated skin disease when
356 potentially relevant
records identified
through the databases
3 additional records were
found from other sources
329 records after
duplicates removed
14 relevant records
indentified
37 records were
excluded based on
their abstracts
51 records retrived
for more detailed
review based on the
abstracts
288 records were
initially excluded
after scannig their
titles
Figure 1 Decision tree outlining the inclusion and exclusion of the identified studies. Some studies reported both cost-benefit and cost-
effectiveness estimates. A PRISMA checklist is provided in Appendix S1.
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Box 2 Glossary
Cost-benefit analysis: A type of economic evaluation
which compares the cost of an intervention to its
monetary benefits. The results are typically expressed
as an internal rate of return or net present value.
Cost-effectiveness analysis: A type of economic eval-
uation in which the cost of an intervention is com-
pared to the quantity of a single non-monetary
effectiveness measure (such as the number of deaths
or cases averted). This avoids the issues associated
with monetising the benefits of healthcare interven-
tions. The results are expressed as a cost per unit of
outcome (see cost-effectiveness ratio).
Cost-effectiveness ratio: A statistic used to sum-
marise the cost-effectiveness of an intervention. It is
calculated by dividing the cost of an intervention by
its effectiveness measure, such as a cost per disability-
adjusted life year (DALY) averted or healthy life year
gained. An incremental cost-effectiveness ratio is cal-
culated by dividing the difference in costs by the dif-
ference in effectiveness outcomes of two alternative
options (it summaries the ‘extra cost per additional
unit of effect gained’).
Community-directed distributors (CDDs): Also
referred to as community drug distributors, these are
volunteers selected by their communities to distribute
treatment.
Disability-adjusted life years (DALYs): A measure
of disease burden that is calculated as the sum of the
years of life lost due to premature mortality and the
years of healthy life lost due to disability. The number
of years of healthy life lost due to disability is calcu-
lated using a disability weight factor (between 0 and
1) that reflects the severity of the disease/disability.
One DALY can be thought of as one year of ‘healthy’
life lost.
Economic costs (opportunity costs): These define
the cost of a resource as its value in its next best alter-
native use (also known as an opportunity cost). This
is a broader conceptualisation of a resource’s value
than its financial cost, as it recognises that using a
resource makes it unavailable for productive use else-
where. The rationale behind economic costs is that
they are intended to represent the full value of all the
resources used for an intervention, and they account
for the fact that resources can have a value that is not
(fully) captured by their financial costs (such as the
‘free’ use of building space provided by Ministries of
Health, and the unpaid time devoted to mass drug
administration by volunteer CDDs). This is
particularly important when considering issues related
to the sustainability and replicability of interventions.
Economies of scale: The reduction in the average cost
per unit resulting from increased production/output; in
this case, the reduction in the cost per treatment as a
result of increasing the number of people treated.
Economies of scope: The reduction in the average
cost per unit resulting when providing multiple goods/
services jointly; in this case, the reduction in the cost
per treatment when delivering more than one inter-
vention at once (e.g. integrated control programmes
or using the CDD platform to deliver more than a sin-
gle intervention). Examples include administering
treatment for both schistosomiasis and soil-trans-
mitted helminthiases within the same programme (in-
stead of by separate vertical programmes).
Financial costs: The actual expenditure (i.e. the
amount paid) for the goods, resources and services
that are purchased.
Friction cost approach: The approach that takes the
employer’s perspective for valuing lost productivity,
and therefore only counts as lost, the hours not
worked by a sick employee before another employee
takes over the work [65]. It is based on the assump-
tion that an ill individual will eventually be replaced
by another healthy worker – therefore, the initial pro-
ductivity levels are restored after this ‘friction period’.
Human capital approach: The approach that takes
the patient’s perspective for valuing lost productivity
and therefore counts all the work they miss, as a pro-
ductivity loss. With this approach, all potential pro-
duction not performed by an individual because of
morbidity or premature mortality is counted as a pro-
duction loss [65].
Indirect costs (productivity costs): Indirect cost rep-
resents the value of productivity losses that result
from illness, treatment, or premature death.
Internal rate of return (IRR): The discount rate
applied to the monetised benefits and costs of an inter-
vention, that makes its net present value equal to zero.
Also known as the economic rate of return (ERR).
Mass drug administration (MDA): The large-scale dis-
tribution of drugs to eligible people within populations
at risk of infection, irrespective of current individual
infection status, i.e. without the need for screening for or
diagnosing infection prior to each treatment round.
Net present value (NPV): The difference between an
intervention’s monetised benefits and its cost. A positive
NPV is an indicator of a successful investment.
Box 2 (Continued)
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quantifying the economic benefits of onchocerciasis inter-
ventions. Kim et al. [60] assumed that severe itching was
associated with a 19% productivity loss and this made
up 65% of their projected income/productivity gains. In
Redekop et al.’s [59] study, the benefits associated with
preventing skin disease represented 22% of the total pro-
jected economic benefit. This assumed that ‘moderate’
skin disease is associated with a 10% productivity loss
and ‘mild’ skin disease is associated with no productivity
loss (Table 5).
For these types of estimates, it is important to consider
which method is used to value the productivity gains.
Estimating the income of individuals affected by NTDs is
challenging, as many of them are in informal employment
(such as subsistence farmers). The analyses identified used
a variety of different methods and sources to approxi-
mate the typical income of someone with onchocerciasis-
associated morbidity (such as the per capita gross domes-
tic product (GDP), subsistence wage, the GDP per capita
of the lowest income quintile). In some cases, the income
source was not clearly stated. It is important to note that
different income sources can give very different estimates
of an individual’s typical income, even when they relate
to the same type of profession/socioeconomic status [40].
Kim et al. [60] also considered the potential income
losses of the informal caregivers of patients with low
vision and blindness (Table 5). Currently, there are very
few primary data quantifying this. Ibe et al. [64] found
that within their survey of onchocerciasis patients in
Nigeria, the average productivity cost among the infor-
mal caregivers was US$3.50 per month (cost year
unavailable).
In all studies productivity gains were estimated using
the human capital approach, which takes the patient’s
perspective for valuing lost productivity. It should be
noted that if the friction cost approach was used (which
takes the employer’s perspective, i.e. only counts as lost,
the hours not worked before another employee takes over
the patient’s work [65]), the estimated productivity gains
would have been lower [66]. There is continued debate
within the field regarding which approach is most appro-
priate [65]. In the context of studies for NTDs, it should
be highlighted that the friction cost approach is hard to
apply to populations that are predominately in informal
employment. Kim et al. [60] and Kim & Benton [58]
made adjustments for employment rates/labour force par-
ticipation within their estimates.
Land use gains. Onchocerciasis caused many people to
abandon the fertile river valleys within the countries
covered by the OCP [2]. It has been estimated that as a
result of OCP interventions, 25 million hectares of aban-
doned arable land was able to be reclaimed for settle-
ment and cultivation [58, 67] (capable of feeding 17
million people annually [67, 68]). Several of the cost-
benefit analyses of the OCP included the projected eco-
nomic benefits resulting from the increased agricultural
output from the reclaimed land. These estimates varied
between US$57–205 million (cost years variable) and
were sensitive to the assumed time horizon and the dis-
count rate (Table 3). The estimate from Kim & Benton
[58] was even higher but the specific value was not sta-
ted (the NPVs (1974–2012) relating only to land use
gains ranged between US$3154 million (using a 3% dis-
count rate) and US$380 million (using a 10% discount
rate)). It should be highlighted that such calculations are
based on various assumptions surrounding rates of agri-
cultural land use and repopulation of the reclaimed
areas (Table 3). It is also important to consider that
onchocerciasis may not have been the sole cause of
depopulation of these areas [9]. Because the same level
of abandonment of river valleys was rarely seen in non-
OCP countries [63], the analyses of the countries cov-
ered by APOC generally did not include the economic
benefits related to land-use gains. One exception is the
report by Haddix [69], which is reported to have re-
evaluated APOC interventions including the estimated
economic benefit resulting from increased agricultural
output (Table 3).
Outpatient services and out-of-pocket expenditure. Indi-
viduals with onchocerciasis-associated morbidity may
seek care from their local health services. Kim et al. [60]
projected the economic benefits of onchocerciasis elimina-
tion resulting from the decreased use of outpatient health
services. They estimated that between 2013 and 2045,
when compared with a control scenario, the elimination
of onchocerciasis in Africa would save the health systems
US$35.9–38.6 million in outpatient service costs, and
save the patients/households US$24.7–26.0 million in
Perspective: The viewpoint from which the interven-
tion’s costs and consequences are evaluated. When
adopting the healthcare providers perspective, the
costs falling outside the healthcare sector are ignored.
In contrast, when adopting the societal perspective, all
relevant cost categories should be included, including
those incurred by the patients.
Time horizon: The time horizon for the analysis;
the duration over which outcomes and costs are
calculated.
Box 2 (Continued)
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out-of-pocket payments (2013 prices) [60]. Primary data
on these costs or on how often individuals with
onchocerciasis seek outpatient care or use local health
services are scarce. An exception is the study by Ibe et al.
[64], which found that the average direct cost incurred
by onchocerciasis patient’s per outpatient visit was US
$14.00 (cost year unavailable), with the majority of this
being for medications.
Interestingly, a study conducted by the World Bank
and WHO reported that on average, people suffering
from the manifestations of onchocerciasis-associated skin
disease were found to spend an additional US$8.10 (cost
year unavailable) on health-related expenditures over a
six-month period compared with those from the same
community without these manifestations [70].
The cost-effectiveness analyses of onchocerciasis
interventions
We identified seven studies performing cost-effectiveness
analyses of onchocerciasis interventions. The majority of
the studies evaluated annual MDA (Table 2). As with the
cost-benefit analyses, variation in the time frames and
discount rates used (Box 3) make it difficult to compare
directly some of the results.
Many older studies have used ‘healthy life years
averted’ as their effectiveness metric (which was based on
reductions in the number of onchocerciasis-related blind-
ness cases). These studies generally assumed that blind-
ness results in complete disability, and that each year
lived with blindness is equal to one full healthy life year
lost, i.e. they assumed a disability weight of 1, which is
equivalent to death (Table 5). One exception to this was
Evans et al. [71], who used a lower disability weight for
blindness of 0.5 (based on empirical evidence that blind-
ness does not result in complete disability and that blind
people are active both socially and economically). These
studies did not appear to quantify the averted burden of
other types of onchocerciasis morbidity (such as skin dis-
ease) (Table 5).
More recent studies have used disability-adjusted life
years (DALYs) averted, a standardised and more compre-
hensive effectiveness metric. When excluding the eco-
nomic value of the donated ivermectin, the estimated cost
per DALY averted of annual MDA varies between US$3
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Box 3 Discounting
Healthcare interventions typically incur costs and gen-
erate health outcomes over a number of years. How-
ever, society does not place an equal value on costs or
health outcomes that occur now compared to those
that occur in the future. This is because there is an
opportunity cost to spending money (as it could be
invested to yield returns) and a desire to have benefits
now rather than in the future. Economic evaluations
therefore need to weight differently costs and health
outcomes that occur in the future.
Discounting is the process used to convert costs or
health outcomes occurring in the future into a present
value [153–155]. It makes costs and benefits occurring
in the future worth less than those in the present. This
allows the comparison of the costs and outcomes
occurring over different time periods. The discount
rate determines the strength of the time preference –
the higher the discount rate the lower the value placed
on future costs/outcomes. Note that adjusting for
inflation (which accounts for the fact that the pur-
chasing power of a currency changes over time) is not
the same as discounting.
When different analyses have used different dis-
count rates, it makes the results harder to compare
them directly. The WHO’s guide to cost-effectiveness
analysis recommends using a 3% discount rate for
both costs and health outcomes (and testing the sensi-
tivity of the results to using a 0% discount rate for
health effects and a 6% discount rate for costs within
the sensitivity analysis) [50]. These recommendations
have engendered greater consistency in the use of dis-
count rates. However, although using the 3%
discount rate has become the standard, there is still
debate within the field, particularly on discounting of
health effects [154, 155].
Box 3 (Continued)
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and US$30 (cost year variable). In comparison the cost
per DALY averted for the MDA delivered within the
Global Programme to Eliminate Lymphatic Filariasis
was estimated to be US$24 when using financial costs
and US$64 when using economic costs including the
value of the donated drugs (2014 prices) [54]. The cost-
effectiveness of onchocerciasis related MDA is also very
favourable compared to other interventions conducted
in low- and middle-income countries (a comprehensive
list of cost-effectiveness estimates for a range of health
interventions in these settings is provided within Horton
et al. [72]).
The most favourable cost-effectiveness estimates relate
to interventions in savannah settings [73]. It is impor-
tant to note that these estimates are not directly general-
isable to onchocerciasis interventions in forest areas,
where ocular pathology and morbidity is considered to
be rarer (Figure 2) (but see [74]). According to this
assumption, intervention cost-effectiveness in the latter
areas would be lower. It should be noted that this
assumption is based on limited data from forest settings
(Figure 2).
The estimated cost-effectiveness ratio was also depen-
dent on the assumed pre-control endemicity level, with
the cost per DALY averted being lower in higher
endemicity settings. In the long term, this range is nar-
rower than might be expected as, although fewer DALYs
are averted in lower endemicity settings, the total cost of
the intervention is also lower (as fewer treatment rounds
will be needed to achieve a similar degree of control or
to reach elimination) (Table 2).
The majority of studies have taken the healthcare pro-
viders perspective, which does not consider the costs fall-
ing on those outside of the healthcare sector. All the cost-
effectiveness analyses appeared to consider only the cost
of the intervention, i.e. none of them included potential
savings to outpatient services, prevented out-of-pocket
costs, or productivity gains that result from prevented
morbidity. Only a few identified studies considered the
economic value of the donated ivermectin. Including this
significantly increases interventions estimated cost and,
therefore, decreases the estimated cost-effectiveness. For
example, Turner et al. [54] found that the estimated cost
per DALY averted increased from US$3–15 to US$29–
Table 5 Summary of the assumed productivity losses and disability weights used for onchocerciasis-associated morbidity
Study Low vision Blindness Skin disease/troublesome itch Source
Assumed productivity loss
Benton & Skinner [67] - 100% -
Kim & Benton [58] - 100% -
McFarland & Murray [124] Not available Not available Not available
Benton [125] - Unclear -
Haddix [69] - Not available -
Kim et al. [60] Patient: 38%
Caregiver: 5%
Patient: 79%
Caregiver: 10%
Severe itching: 19% [128, 129, 134–137]
Redekop et al. [59] 38% 79% Moderate: 10% Mild: 0% [128, 129]
Healthy life year weights†
Prescott et al. [126, 127] - 1.0 -
Evans et al. [71] - 0.5 -
Benton [125] - 1.0 -
DALY weights†
GBD 1990 0.245 0.488 (treated) 0.600
(untreated)
0.068 GBD 1990 [138]
GBD 2000 [138] 0.224 (treated) 0.282
(untreated)
0.60 0.068 GBD 2000 [138]
McFarland & Murray [124] Not available Not available Not available
Turner et al. [73] 0.170 0.594 0.068 GBD 2004 [139]
Coffeng et al. [30] 0.282 0.594 0.068 GBD 2004 [139]
Coffeng et al. [78] 0.033 0.195 0.108‡ GBD 2010 [140]
de Vlas et al. [141] 0.101§ 0.101§ 0.079‡ GBD 2010 [140]
DALYs, disability-adjusted life years; GBD, Global Burden of Disease Study.
†Reflect the severity of the disease sequelae with 0 representing perfect health and 1 representing death.
‡Used a weight representing an overall average for skin disease across more finely disaggregated strata/severity levels.
§Used a weight representing an overall average for visual morbidity (i.e. the weight was not stratified by ‘low vision’ and ‘blindness’).
Where relevant additional studies that were not performing economic evaluations were included for comparison.
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133 (2012 prices) when including the economic value of
donated ivermectin (which would still be classed as cost
effective). It is also debatable when the value of iver-
mectin should be included within an economic evalua-
tion, particularly under the healthcare providers
perspective.
Numerous approaches have been used to quantify the
effectiveness of onchocerciasis interventions. Many older
studies based the effectiveness on reductions in the inci-
dence of blindness on limited empirical data and pro-
jected similar putative reductions with continuing
intervention. More recent studies have used mathematical
transmission models to project the ongoing future effec-
tiveness of interventions more accurately, explicitly mod-
elling disease dynamics through time [75]. The two main
models used for this purpose (EPIONCHO and ONCH-
OSIM) are described in Basa~nez et al. [76]. An important
advantage of this approach is the capacity to account for
the indirect benefits/herd effects of interventions (the indi-
rect benefit afforded to individuals not directly targeted
by an intervention that arises from the population-wide
reduction in transmission) [75]. These models can also
account for longer time horizons, accounting for the con-
tinued benefits of interventions even after the control pro-
gramme has stopped.
DALY calculations. DALYs are calculated as the sum of
two components; the years of healthy life lost due to
disability, and the years of life lost due to premature
mortality [77]. In a DALY calculation, the years of
healthy life lost due to disability are calculated using
standardised disability weights, ranging between 0 and 1.
This reflects the severity of the different disease sequelae,
with 0 representing perfect health and 1 representing
death. The disability weights used for onchocerciasis
DALY calculations have changed over time (Table 5).
For the 2010 GBD study, the disability weights for
vision loss were notably decreased compared to previous
studies, whereas the weights for skin disease were
increased (Table 5). Consequently, Coffeng et al. [78]
found that when using the newer weights, the estimated
number of DALYs averted by APOC (2000–2015)
increased by 9% compared to when using the GBD 2004
weights. Moreover, skin disease, instead of eye disease,
became the most important contributor to the burden of
onchocerciasis. Since the GBD 2010 study, onchocercia-
sis-associated skin disease has not been assigned a specific
single disability weight, and more general disfigurement
health states (stratified by three severity levels and
whether or not the disfigurement is associated with itch
or pain) are used. When using these updated GBD dis-
ability weights, studies have typically estimated an overall
average skin disease weight (Table 5). Subsequent GBD
studies have made additional changes to the DALY calcu-
lation for onchocerciasis, particularly relating to the
weights attributed to the different types of skin disease
Savannah settings
16
(a) (b)
Pr
ev
al
en
ce
 o
f o
nc
ho
ce
rc
ia
sis
-a
ss
oc
ia
te
d
bl
in
dn
es
s 
in
 th
os
e 
ag
ed
 ≥
5 
(%
)
Pr
ev
al
en
ce
 o
f o
nc
ho
ce
rc
ia
sis
-a
ss
oc
ia
te
d
bl
in
dn
es
s 
in
 th
os
e 
ag
ed
 ≥
5 
(%
)
Prevalence of microfilariae in those
aged ≥5 (%)
Prevalence of microfilariae in those
aged ≥5 (%)
14
12
10
8
6
4
2
0
0 20 40 60 80 100 0 20 40 60 80 100
16
14
12
10
8
6
4
2
0
Forest/mixed settings
Figure 2 The relationship between the prevalence of onchocerciasis-associated blindness and the prevalence of skin microfilariae in
savannah (a) and forest/mixed forest-savannah settings (b). The figures were adapted from Figures S3 and S4 in Coffeng et al. [30].
The data were originally taken from [142–148].
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and the types of skin disease included [79]. A more
detailed overview of the changes to the GBD study
methodology used to calculate DALYs is presented in
[80–82].
Several studies have accounted for the excess mortality
associated with onchocerciasis visual morbidity [3] within
their DALY calculations. However, it has generally not
been considered that irrespective of visual morbidity,
there is an increased risk of mortality associated with
increasing microfilarial load, particularly in children and
young adults aged below 20 years [4, 5]. Estimates of
onchocerciasis burden (and the cost-effectiveness of its
control) would generally increase if this onchocerciasis-
associated excess mortality were taken into account. For
example, Turner et al. [83] found that, depending on the
pre-control endemicity level, excess mortality accounted
for 29–43% of the estimated pre-control DALY burden
of onchocerciasis. If this had not been included, the esti-
mated cost-effectiveness would have been reduced sub-
stantively.
Cost-effectiveness thresholds. In cost-effectiveness analy-
ses, the cost per DALY averted is compared to a willing-
ness to pay threshold to determine whether an
intervention is cost effective. However, the most appro-
priate cost-effectiveness thresholds are debated and
remain somewhat arbitrary [84–86]. The cost-effective-
ness threshold set by the WHO-CHOICE [87] (a cost per
DALY averted < 3 times the country’s GDP per capita) is
now considered to be too high [84–86, 88, 89]. Most
analyses within the NTD field have not used it [40, 41,
90], many opting instead for the more conservative cost-
effectiveness threshold set by the World Bank [91] (≤ US
$251 per DALY averted, when adjusted for inflation to
2016 prices [92]). Interestingly, recent analyses have indi-
cated that a cost-effectiveness threshold closer to < ½ the
country’s per capita GDP would be more appropriate for
low-income countries [88, 93]. For comparison, the Dis-
ease Control Priorities project (Third Edition) used a
threshold of US$200 per DALY averted to identify prior-
ity interventions for consideration in low-income coun-
tries [94]. Despite this ambiguity on cost-effectiveness
thresholds, onchocerciasis interventions would remain
classed as cost effective by any of the proposed measures.
Elimination and evaluation of alternative interventions
Traditional cost-effectiveness analyses of new interven-
tions evaluate their incremental effectiveness and incre-
mental cost compared to the current practice (calculating
incremental cost-effectiveness ratios, Box 2). This frame-
work has been widely and successfully used to evaluate
the comparative cost-effectiveness of new intervention
strategies for disease control. However, this incremental
cost-effectiveness framework is less informative and
somewhat ill-suited for disease elimination or eradication
programmes. For example, Turner et al. [73] found that
that increasing the treatment frequency of ivermectin dis-
tribution from once to twice per year yielded very small
incremental health gains (only a 3–4% increase in the
number of DALYs averted) but could have a large influ-
ence on a programme’s overall total cost and duration
(Table 2). In such cases, where an intervention is aimed
at accelerating and sustaining elimination, an incremental
cost-effectiveness ratio may not reflect its true value.
Instead, as applied in Turner et al., the absolute cost of
the intervention and the time it takes to achieve the
desired elimination goal can be more informative. The
same framework was applied to an economic evaluation
of moxidectin [95] (Table 1), a newly registered treat-
ment for onchocerciasis (https://www.medicinesdevelop
ment.com/news-180613.htm). Kastner et al. [96] have
also highlighted that the number of DALYs averted may
not fully capture the long-term consequences and broader
benefits of disease eradication programmes.
Another important aspect to consider when evaluating
elimination programmes is the time horizon of the anal-
ysis [40]. This is because the costs of elimination pro-
grammes are typically higher than would be needed for
disease control [97]. After elimination is certified, the
estimated cost-effectiveness of an elimination programme
will steadily increase as the discounted benefits continue
to accumulate but the costs have stopped (with the
potential exception of ongoing surveillance). The bene-
fits and potential future cost savings resulting from
achieving elimination/eradication are not infinite [40,
73], as the costs/cost savings being considered must be
restricted within a suitable time horizon and are typi-
cally discounted into the future (Box 3). In contrast, for
disease control programmes, the intervention costs will
typically be incurred for the full- time horizon. Because
of this, elimination programmes can be cost-saving in
the long term. However, it can take time for the longer-
term benefits and cost savings associated with achieving
elimination to outweigh the initial increases in costs
associated with achieving elimination. Consequently,
with short-term time horizons, elimination programmes
are unlikely to be more cost effective than disease con-
trol programmes.
Eradication investment cases have been developed for a
number of NTDs [98], including onchocerciasis [53, 60,
99]. These latter studies have compared onchocerciasis
control and elimination/eradication scenarios and have
quantified the duration of the programme, its financial
20 © 2019 The Authors. Tropical Medicine & International Health published by John Wiley & Sons Ltd.
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and economic cost, the number of ivermectin treatments
required, the workload of the community healthcare
workers/volunteers, costs related to outpatient healthcare
services, and the productivity gains resulting from pre-
venting onchocerciasis-associated morbidity. The overall
conclusions of these studies are that eradication and elim-
ination of onchocerciasis are both justifiable on both
cost-effectiveness and benefit-cost analysis grounds, and
that eradication tends to be more favoured over the long-
term time horizon.
Sensitivity analysis
The majority of identified studies either did not perform a
sensitivity analysis or undertook only a univariate analysis,
changing one parameter at a time to evaluate its impact
independent of other parameters. The main exceptions to
this were Redekop et al. [59] and Kim et al. [60].
Redekop et al. [59] performed probabilistic sensitivity
analysis (PSA) in which the values of three input parame-
ters (the estimates of disease prevalence in 2010, the per-
centage of productivity loss/the amount of out-of-pocket
payments, and the patient’s income) were allowed to vary
simultaneously. Kim et al. [60] first conducted a one-way
deterministic sensitivity analysis to examine which
parameters are key drivers. They then conducted PSA to
assess the robustness of the results to the joint uncertain-
ties around all selected parameters [60].
Limitations of this analysis
A potential source of bias of the search strategy is that it
did not capture economic evaluations published outside
of the searched electronic databases (i.e. grey literature
such as policy documents/reports, and many non-English
language publications etc.). Efforts were made to min-
imise this bias by searching the bibliographies of selected
studies. There could also be a degree of publication bias,
with economic evaluations with negative or unfavourable
results less likely to be published. It should be noted that
the selection of studies was not performed independently
by two researchers.
Areas of further research
The results of the systematic review highlight that the
standard onchocerciasis control strategies are consistently
found to be very cost effective. However, there are some
important research gaps that need further research.
Data on intervention costs and the economic burden of
onchocerciasis. The costs of MDA delivery have been
shown to vary across different settings [31, 32, 37, 41,
100]. This variation potentially affects the generalisability
of any cost-effectiveness/cost-benefit analysis [75], and
future studies need to quantify the impact of this in
greater detail. It should be noted that the costs of con-
ducting MDA in areas where onchocerciasis and loiasis
are co-endemic may be higher – due to the need for
enhanced surveillance and community sensitisation.
In addition, further studies are needed to investigate
how integrating NTD control programmes [31, 39] may
influence the costs/cost-effectiveness of implementing dif-
ferent control strategies [37, 40]. There is notable varia-
tion in the methodological approaches used to quantify
the economic costs incurred by CDDs. It would be bene-
ficial if future studies adopted more consistent
approaches (outlined in [52]).
The cost of onchocerciasis control programmes will
likely increase significantly as they approach the ‘last
mile’ towards elimination [37]. This is partly because of
the increase in the costs resulting from expanding the
programmes to target harder-to-reach areas/groups (disec-
onomies of scale) [37]. This is an important issue for
NTD programmes in general, and further costing studies
are needed to quantify it.
Further studies are needed on quantifying the medical
costs incurred by those with onchocerciasis seeking treat-
ment. Such studies could yield more robust estimates of
the economic benefits of onchocerciasis control [60]. It
would also be beneficial if future studies sought to quan-
tify the productivity losses incurred by informal caregivers,
not just those caring for the blind. Note also that with the
rise in sophistication of health systems in the endemic
countries, the health system costs and the contribution of
out-of-pocket expenses are both likely to rise [101].
Our analysis also revealed that studies used cost data
collected in different years, but it was not always clear if
and how costs were adjusted for inflation. Future studies
should report this more explicitly [102] and within a
given study the costs would be standardised to a consis-
tent year.
Economic evaluations of alternative interventions. In
certain epidemiological and programmatic circumstances,
alternative strategies to annual MDA will be required to
achieve the current goals for onchocerciasis control/elimi-
nation [21, 22, 103]. Such strategies include increased
frequency of MDA (up to four times per year), localised
low-cost vector control and treatment strategies using
moxidectin, anti-Wolbachia therapies and new macrofila-
ricidal drugs [104–106]. However, there currently are
very few costing studies and economic evaluations relat-
ing to these alternative interventions [32, 107]. Studies
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are needed to evaluate the cost and cost-effectiveness of
such strategies. When such studies are performed, it will
be vital that the generalisability of the estimated cost
across different programmatic settings is considered [37].
It will also be important to consider the value of these
alternative interventions not only in reducing the disease
burden where they are implemented, but also in their
capacity to help eliminate onchocerciasis more quickly.
This will be particularly important in reducing the risk
that ‘hot spots’ of sustained transmission seed and re-
establish transmission in areas where onchocerciasis has
been eliminated.
This area of research is particularly important for inter-
ventions targeting onchocerciasis in Loa loa co-endemic
areas. It has been recently predicted that, at the 2025
horizon, two-thirds of onchocerciasis remaining cases will
be living in hypoendemic areas for onchocerciasis where
the risk of Loa-related post-ivermectin severe adverse
events (SAEs) has so far been considered to outweigh the
benefits for the communities. The paradigm shift from
control to elimination implies that hypoendemic areas
start receiving community treatment with ivermectin. A
test-and-not-treat strategy for onchocerciasis has recently
been successfully piloted in a health area of Central
Cameroon where community-directed treatment with
ivermectin had to be permanently halted after a series of
SAEs occurred in 1999 [108]. Costing studies of this
approach are ongoing. Critical questions when addressing
the cost-effectiveness of this intervention include the
counterfactual – what it would cost to leave all those
populations untreated? – and cost-effectiveness relative to
other locally important health issues.
Future economic analyses of alternative interventions
need to be tailored to the key policy questions from the
different decision makers and stakeholders. These differ-
ent questions may require different methodological
approaches and perspectives for the analyses. This further
emphasises the need for transparent reporting of method-
ology in economic evaluations.
Quantifying the health benefits of interventions. Many
older studies only quantified the health and economic
benefits resulting from the number of blindness cases
averted. More advanced disease models have been devel-
oped that account for averted visual impairment, skin
disease, and excess human mortality. However, further
refinements are needed to better capture the relationship
between infection and skin disease [109], and to account
for related neurological disorders such as epilepsy and
nodding syndrome [6–8].
When evaluating an intervention aimed at reducing
morbidity, the number of DALYs averted is often the best
effectiveness metric, as it allows cost-effectiveness esti-
mates to be directly compared to estimates relating to
other interventions/diseases as well as to standardised
cost-effectiveness thresholds. This makes the results of
economic evaluations easier to interpret by policymakers.
However, DALYs do have limitations and there are con-
troversies surrounding their calculation [110]. For
example:
• The universal disability weights do not account for
how the local context may influence the burden of a
disease. Consequently, the potential that the burden of
a disease or its sequelae may be worse for those that
are living in poverty is not accounted for. It has been
argued that this aspect of DALY calculations may sig-
nificantly underestimate the burden of poverty-related
diseases [110, 111].
• The DALY disability weights do not fully account for
the psycho-social implications of a disease or its
sequelae [112] and its overall impact on quality of life.
They also do not explicitly account for the impact of
the disease on patients’ informal caregivers. In particu-
lar, the updated disability weight for blindness (de-
creasing from 0.60 to 0.19) has been controversial
within the field [113, 114]. A possible reason for this
significant change is that within the updated GBD
framework (post-GBD 2010), the disability weights
are intended to be solely measures of losses of ‘opti-
mal health’ and are not intended to represent losses of
well-being/welfare [80, 115].
Interestingly, the same age group (those aged below
20 years) for which there is a statistically significant
higher risk of mortality for a given microfilarial load in
comparison to those aged 20 years and older [5], is the
group with the onset and higher incidence of nodding
syndrome, a type of epilepsy that is increasingly recog-
nised as associated with onchocerciasis [116, 117]. Pre-
liminary studies of the disease burden of onchocerciasis-
associated epilepsy have been conducted [118]. These
studies should be followed by economic evaluations of
both onchocerciasis-associated epilepsy and the impact of
onchocerciasis interventions.
Joint/auxiliary benefits. Ivermectin is a broad-spectrum
antiparasitic drug that also has an impact on other co-
endemic parasitic infections (such as soil-transmitted
helminthiases, lymphatic filariasis, loiasis and scabies).
Krotneva et al. [119] assessed the auxiliary benefits of
APOC and estimated that between 1995 and 2010, iver-
mectin mass treatment (in APOC regions) cumulatively
averted approximately 500 000 DALYs from co-endemic
22 © 2019 The Authors. Tropical Medicine & International Health published by John Wiley & Sons Ltd.
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soil-transmitted helminth infections, lymphatic filariasis,
and scabies. This highlights that the overall
cost-effectiveness of onchocerciasis interventions may be
even higher than previously reported. Further quantifica-
tion of these auxiliary benefits would be useful to
improve estimations of the impact of onchocerciasis
interventions.
Modelling and elimination thresholds. Dynamic trans-
mission models have an important role, particularly for
the evaluation of novel interventions and how they com-
pare to the standard strategy of MDA with ivermectin.
These models (reviewed in Basa~nez et al. [76]) have
undergone extensive refinement in recent years to better
capture parasite population dynamics during interven-
tions [120] and to produce more robust projections on
the likelihood of elimination. These modelling efforts will
be particularly useful in identifying epidemiological and
programmatic circumstances in which alternative strate-
gies will be required to reach elimination (for example in
highly endemic settings, settings with suboptimal
responses to ivermectin [121, 122], or where the initia-
tion of programmes has previously been delayed [103]).
Moreover, transmission models (as opposed to so-called
‘static’ models) capture explicitly our current understand-
ing of the changing parasite dynamics during interven-
tions [75].
Conclusions
The cost benefit and cost effectiveness of onchocerciasis
interventions have consistently been found to be very
favourable. This finding provides strong evidential sup-
port for the ongoing efforts to eliminate onchocerciasis
from endemic areas.
MDA against other NTDs has also been found to be
cost effective [40, 54, 90] and, therefore, a logical next
step would be to quantify the net cost-effectiveness of
more closely integrating these programmes, which are
already often running side-by-side in co-endemic areas.
Indeed, the primary rationale for the aggregation of
common infectious diseases of the poor under the
denomination of ‘Neglected Tropical Diseases’ was the
perception that treating many diseases using a single
common delivery system would be inherently cost effec-
tive. It would be important to future policy making to
explore the evidence base for that perception. Further
systematic reviews of this type on other NTDs would
also be useful.
We identify three main research gaps in this area. First,
the need to be more inclusive in quantifying burden. Origi-
nally, studies only quantified the benefits of preventing
blindness, and then also captured onchocerciasis-associated
skin disease. An improved understanding of other factors,
such as onchocerciasis-associated epilepsy [117, 118] would
enhance the precision of the calculated benefits. Second, the
evaluation of interventions targeting Loa loa co-endemic
areas which will become more important in the end-game
for elimination. Finally, the need to increase the compara-
bility of economic analyses. Greater adherence to standard-
ised guidelines for reporting the results of economic
evaluations (such as CHEERS for cost-effectiveness analysis
[123]) would be beneficial and increase the reliability and
reproducibility of reported findings.
Programmes to eliminate onchocerciasis have always
been in the vanguard of global efforts to eliminate dis-
eases of poverty. Lessons learned here from the economic
analysis of onchocerciasis programmes have direct rele-
vance to the design of programmes addressing all the
other NTDs.
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